NAVER D2SF backs ImpriMed, Munice in global healthcare push

What's the deal? NAVERDealroom has a profile for this one. Try Dealroom → D2SF, the startup arm of South Korea's NAVER, has made new investments in two global healthcare startups: precision-medicine firm ImpriMed and sleep-management company MuniceDealroom has a profile for this one. Try Dealroom →. The corporate venture unit announced the deals on September 18.

What do they do? ImpriMed analyses patients' cancer cells outside the body, combining immunophenotype, genomic, and clinical data to guide treatment decisions. Munice runs RenightDealroom has a profile for this one. Try Dealroom →, an AI-based personalised sleep app that tailors sound to a user's physical and psychological state.

By the numbers. ImpriMed is building AI models on more than 3.5 million patient records. Munice has gathered over 8.8 million sleep-data points and, as of September 2026, passed $5 million in annual recurring revenue with more than 77,000 paying subscribers globally.

Why now? ImpriMed is preparing North American approvals, targeting US Food and Drug Administration and CLIA clearance within the first quarter of 2027, with plans to commercialise in the US first. It has also built a partnership with the Mayo ClinicDealroom has a profile for this one. Try Dealroom →.

What's the endgame? ImpriMed is focusing on blood cancers and blood-borne infections, and runs a contract research organisation business alongside a pet healthcare arm active in about 600 animal hospitals across the US, Canada, the UK, France, and South Korea. Munice plans to expand beyond Japan and Taiwan into wider Asia, the Middle East, and North America.

Localisation results. Munice reached number one in the App Store's health and fitness category in Japan six months after entry. In Taiwan, which it entered in May 2026, it topped the same category within two weeks.

What's NAVER D2SFDealroom has a profile for this one. Try Dealroom → building? The unit has previously invested in healthcare startups including Sounderble HealthDealroom has a profile for this one. Try Dealroom →, Prana QDealroom has a profile for this one. Try Dealroom →, and Nuvi LabDealroom has a profile for this one. Try Dealroom →. It plans to strengthen a community where portfolio companies share experience across research and development, regulatory approvals, and market entry.

"ImpriMed is turning the potential of precision medicine into reality in the North American market based on clinical evidence and business capability, and Munice is showing the potential of B2C healthcare tailored to each market in Japan and Taiwan," said Yang Sang-hwan, head of NAVER D2SF (translated from Korean).

The signal: The pair of deals shows NAVER D2SF sharpening a healthcare portfolio built around startups chasing global markets — from regulated precision medicine to consumer sleep apps — and betting that shared go-to-market experience can accelerate their overseas expansion.

Image credit: Centers for Disease Control and Prevention